Lisata Therapeutics Stock Current Liabilities
| LSTA Stock | USD 2.32 0.06 2.65% |
Lisata Therapeutics fundamentals help investors to digest information that contributes to Lisata Therapeutics' financial success or failures. It also enables traders to predict the movement of Lisata Stock. The fundamental analysis module provides a way to measure Lisata Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lisata Therapeutics stock.
Lisata |
Lisata Therapeutics Company Current Liabilities Analysis
Lisata Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Lisata Therapeutics has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Lisata Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lisata Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lisata Therapeutics could also be used in its relative valuation, which is a method of valuing Lisata Therapeutics by comparing valuation metrics of similar companies.Lisata Therapeutics is currently under evaluation in current liabilities category among its peers.
Lisata Fundamentals
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (4.95) % | ||||
| Current Valuation | (11.63 M) | ||||
| Shares Outstanding | 8.62 M | ||||
| Shares Owned By Insiders | 18.74 % | ||||
| Shares Owned By Institutions | 9.11 % | ||||
| Number Of Shares Shorted | 26.7 K | ||||
| Price To Book | 0.66 X | ||||
| Price To Sales | 19.48 X | ||||
| Revenue | 1000 K | ||||
| Gross Profit | 1000 K | ||||
| EBITDA | (22.23 M) | ||||
| Net Income | (19.98 M) | ||||
| Cash And Equivalents | 72.99 M | ||||
| Cash Per Share | 18.07 X | ||||
| Total Debt | 137 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 22.33 X | ||||
| Book Value Per Share | 3.52 X | ||||
| Cash Flow From Operations | (19.36 M) | ||||
| Short Ratio | 1.84 X | ||||
| Earnings Per Share | (2.40) X | ||||
| Price To Earnings To Growth | (0.02) X | ||||
| Target Price | 17.0 | ||||
| Number Of Employees | 26 | ||||
| Beta | 1.16 | ||||
| Market Capitalization | 19.48 M | ||||
| Total Asset | 35 M | ||||
| Retained Earnings | (548.07 M) | ||||
| Working Capital | 28.96 M | ||||
| Net Asset | 35 M |
About Lisata Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lisata Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lisata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lisata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lisata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lisata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lisata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lisata Therapeutics Stock:Check out Lisata Therapeutics Piotroski F Score and Lisata Therapeutics Altman Z Score analysis. For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. If investors know Lisata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lisata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lisata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lisata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lisata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.